非小细胞肺癌疾病负担研究进展

Progress in Research on Disease Burden of Non-small Cell Lung Cancer

目的:综合回顾近几年国内外非小细胞肺癌疾病负担的相关文献,探讨有关非小细胞肺癌疾病负担研究进展,以期为今后的相关研究提供新的思路,同时为卫生保健部门降低可控因素的费用从而降低总的卫生费用提供理论支持。方法:在中国期刊全文数据库(1990-2014年)中以"非小细胞肺癌"和("疾病负担"或"伤残调整生命年")为检索词;在Elsevier、Pub Med、Medline等外文数据库(1990-2014年)中以"non-small cell lung cancer"AND("burden of disease"OR"disability-adjusted life years(DALY)")为检索词,检索相关文献。结果:共纳入8篇符合要求的文献,其中4篇国外文献研究较全面,样本量较大,质量较好。国内研究较少,缺乏相关DALY指标。结论:无论是国外还是国内的研究均表明非小细胞肺癌是疾病负担非常严重的疾病之一,且治疗过程中药费占据经济负担的很大比重。建议相关部门从降低药费着手从而为降低总的医疗费用提供解决办法,同时,应当更加注重肺癌的早期防治。

Objective： The paper is a comprehensive review of the study on disease burden of non-small cell lung cancer（NSCLC） in recent years worldwide to provide new ideas for the relevant research in future, and to provide a theoretical support to the healthcare sectors to reduce the cost of the controllable factors so as to reduce the total health expense. Methods： The literatures published in Chinese in CNKI, Elsevier, Pub Med and Medline during 1990- 2014 were searched using ＂non-small cell lung cancer ＂AND（ ＂burden of disease ＂ OR ＂disability-adjusted life years（DALY） ＂） as keywords. Results： Eight literatures were obtained, of which 4 paper about studies abroad included a large quantity of samples and are of high quality. However, few studies in China are reported,and the indexes of DALY are in lack. Conclusion： Whether foreign or domestic studies show that NSCLC is one of diseases with high burden, and the cost of medicine account for a large proportion of the economic burden. It is suggested to decrease the drugs cost so as to provide a measure to decrease the overall health care costs.Meanwhile, more attention should be paid to early prevention and treatment of lung cancer.